[On the use of an anabolic hormone in the acute myocardial infarction. Experimental trial on 486 patients (author's transl)].
An anabolic hormone, methandrostenolone, was shown to be able to decrease significantly the cicatrization-time on animals with induced sperimental acute myocardial infarction (AMI). A controlled clinical trial was performed on group of 246 patients affected by AMI, giving them methandrostenolone at dose of 25 mg im.m. per day, for the first ten days from the beginning of symptoms. An omogeneous group of 240 patients with AMI was used as control. The mortality rate resulted 13,4% in the treated group 18,7% in the control's. 10 patients in the treated group (4,2%) died of cardiac failure versus 17 (7,1%) in the control group, 9 (3,7%) of cardiac rupture in the former versus 6 (2,4%) in the latter. As far as these differences are concerned statistical significance was not reached. A larger number of patients would be requested.
D000368:Aged; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D008297:Male; D008696:Methandrostenolone / Q000627:therapeutic use*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*
D008696:Methandrostenolone
Sull'impeigo di un anabolizzante nella fase acuta dell'infarto miocardico. Sperimentazione clinica controllata su 486 pazienti